The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

 
• By Sarah Karlin-Smith
dark forest with fallen tree
If a dozen Humira biosimilars launch, but formulary design doesn’t incentivize uptake, does the biosimilar pathway take a bow? • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics